drugset / Trial / NCT06108050
JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This Phase 1 first-in-human study will investigate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary antitumor activity of JZP898 monotherapy as well as JZP898 in combination with pembrolizumab in adult participants with advanced or metastatic solid tumors.
Timeline
- Start
- 2023-11-07
- Primary completion
- 2027-11-30
- Completion
- 2028-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JZP898 | Unknown | — | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | — | — |